查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858224

RSV诊断市场依检测类型、产品、技术平台、最终用户、检体类型、通路和年龄组别划分－全球预测（2025-2032年）

RSV Diagnostics Market by Test Type, Product, Technology Platform, End User, Sample Type, Distribution Channel, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，RSV 诊断市场将成长至 24 亿美元，复合年增长率为 9.37%。

关键市场统计数据
基准年 2024 11.7亿美元
预计年份：2025年 12.8亿美元
预测年份 2032 24亿美元
复合年增长率 (%) 9.37%

对呼吸道合胞病毒（RSV）诊断优先事项、技术融合、临床效用、影响医疗机构检测采用的运作因素进行全面分析

本执行摘要摘要了呼吸道融合细胞病毒(RSV) 诊断的最新趋势，综合分析了对检查室主任、临床负责人和产品负责人至关重要的临床、技术和商业性发展动态。 RSV 诊断已从疫情驱动的重点领域转变为呼吸道疾病管理的重要组成部分，这得益于监测手段的改进、就地检验能力的提升以及临床指南的不断完善。实施过程体现了临床必要性。及时且准确的检测结果有助于指导治疗决策、机构隔离和公共卫生应对措施。本报告还提供了一个分析方法框架，重点关注诊断路径、技术实施、产品生态系统和最终用户需求。

技术融合、分散式检测能力和不断发展的临床工作流程将如何重塑呼吸道合胞病毒（RSV）的诊断和治疗路径决策

呼吸道合胞病毒（RSV）的诊断格局正在经历变革，这主要得益于技术创新、临床实践的改变以及系统层面提高呼吸道病原体快速检测能力的迫切需求。分子诊断平台正从集中式检查室转移到更贴近患者的分散式机构，实现更早期的检测和更有针对性的临床干预。同时，化学冷光和萤光免疫检测分析灵敏度的提升正在缩小速度和准确性之间的差距。等温扩增技术和改进的侧向流动化学方法的应用代表了更广泛的趋势。曾经因安装环境而分散的各种技术正在融合，以满足不同应用场景的需求。

评估2025年美国关税调整对供应链韧性、筹资策略和诊断连续性的累积营运影响

2025年美国关税调整和贸易政策变化对整个诊断供应链产生了连锁反应，影响了仪器、试剂盒和试剂的筹资策略、采购决策和成本结构。製造商和经销商的零件采购方式发生了变化，促使他们重新评估供应商组合，并加快关键零件（如分析仪、PCR仪、缓衝液和酵素）的近岸外包。因此，采购团队更重视供应商多元化和合约弹性，以降低未来贸易相关干扰的影响。

整合細項分析以指导策略重点：将测试类型、产品生态系统、技术平台、终端用户环境、检体类型、分销管道和患者人口统计资讯连结起来

严谨的細項分析识别出呼吸道合胞病毒（RSV）诊断领域中价值和风险集中的区域。按检测类型划分，免疫检测、分子检测和快速检测在性能和应用方面有显着差异。免疫检测可再细分为化学冷光免疫检测、酵素免疫分析法及免疫萤光法法。分子检测进一步分为等温扩增、次世代定序和即时聚合酵素链锁反应，而快速检测则根据横向流动化验和微流体控技术进行区分。每个子类别在通量、灵敏度和照护现场适用性方面都存在独特的权衡，这凸显了检查室和临床医生应优先投资的领域。

美洲、欧洲、中东和非洲以及亚太地区的区域诊断重点和操作实践将决定部署路径和供应策略。

区域趋势影响诊断重点、报销政策和营运限制，直接影响技术采纳和部署策略。在美洲，临床网路和医院系统优先考虑整合的检查室工作流程和快速获取确诊性分子检测，而门诊诊所和社区医疗机构则越来越多地采用就地检验。製造商正致力于开发可扩展的仪器平台以及相容的试剂盒和试剂，以支持不同临床层面的广泛应用。

诊断试剂製造商和专业供应商如何协调平台策略、伙伴关係和供应链能力，以加速临床应用并支援多元化的终端用户

领先的诊断公司和专业供应商持续利用平台优势和策略伙伴关係关係，推动呼吸道合胞病毒（RSV）检查室，并简化采购流程。与学术机构和临床网络进行策略合作，将有助于检验工作，并在监管允许的情况下加速临床应用。

为诊断产业领导者提供实际的策略行动，以增强供应链韧性、检验临床效能，并使产品适应不同的临床环境和使用者需求。

产业领导者应优先采取一系列切实可行的措施，将诊断科学转化为持续的临床影响和商业性可行性。首先，透过多元化组件采购和协商能够适应关税波动和物流中断的灵活合同，增强供应链的韧性。其次，投资于与学术和医院检查室的检验伙伴关係，以产生关键检体类型（例如鼻咽拭子和唾液）的独立表现数据，并证明其在成人、老年人和儿童群体中的临床效用。这些合作将有助于促进临床认可，并为医保报销谈判奠定基础。

透明的多来源调查方法，结合文献综述、监管审查、技术检验和相关人员访谈，可提供严谨的诊断见解和清晰的细分。

本研究整合了同行评审文献、监管申报文件、临床指南文件、产品技术规范以及对关键相关利益者的访谈，从而构建了呼吸道合胞病毒（RSV）诊断的多维度视角。调查方法结合了近期科学文章和技术白皮书的系统性回顾，以及检查室主任、临床终端使用者和产业专家的结构化访谈。分析重点在于利用独立报告的效能数据和实际应用回馈对技术声明进行交叉检验。

诊断技术优势、营运需求和策略重点的整合将决定呼吸道合胞病毒（RSV）检测在临床和商业性的持续成功。

总之，呼吸道合胞病毒（RSV）诊断格局取决于技术能力与实际应用之间的动态平衡。分子诊断、免疫检测分析和快速检测方法各自为临床路径带来独特的优势，它们的融合为透过更快、更准确的检测来改善患者预后创造了机会。供应链和贸易趋势凸显了建构弹性采购和灵活营运规划的必要性，而不同地区和终端用户的多样性则要求产品设计和商业化采取量身定制的方法。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • RSV的快速分子检测正在迅速普及，从而实现分散式患者管理和快速治疗决策。
  • 利用整合了呼吸道合胞病毒 (RSV)、流感病毒和 SARS-CoV-2 检测的多重呼吸道病毒检测板，进行全面的季节性病毒监测
  • 采用等温扩增技术可提高门诊检测的敏感度并缩短检测週转时间
  • 远端医疗平台和远端患者监护解决方案推动了家用呼吸道合胞病毒检测套组的需求。
  • 本院加强对儿童和新生儿呼吸道合胞病毒筛检通讯协定的重视，旨在降低严重感染率并优化资源分配。
  • 数位医疗和人工智慧驱动的分析工具的出现，提高了呼吸道合胞病毒诊断检查室的准确性和工作流程效率。
  • 临床试验中用于呼吸道合胞病毒基因分型和抗病毒抗药性分析的次世代定序检测获得监管部门核准
  • 新冠感染疾病后呼吸道合胞病毒季节性模式变化对检测量及公共卫生监测策略的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. RSV诊断市场按检测类型划分

  • 免疫检测
    • 化学冷光免疫检测
    • 酵素免疫分析法
    • 萤光
  • 分子检测
    • 等温扩增
    • 次世代定序
    • 即时聚合酵素链锁反应
  • 快速检测
    • 横向流动化验
    • 微流体检测

9. RSV诊断产品市场

  • 装置
    • 分析器
    • PCR装置
  • 成套工具
    • 唾液采集套装
    • 拭子采集套装
  • 试剂
    • 缓衝溶液
    • 酵素

10. 依技术平台分類的呼吸道合胞病毒 (RSV) 诊断市场

  • ELISA
  • 萤光
  • PCR

第十一章 RSV 诊断市场（按最终用户划分）

  • 学术机构
  • 诊所
  • 诊断检查室
  • 居家照护
  • 医院检查室

第十二章：依检体类型分類的呼吸道合胞病毒（RSV）诊断市场

  • 血
  • 鼻咽拭子
  • 唾液

第十三章 RSV诊断市场（依通路划分）

  • 离线
  • 在线的

第十四章 依年龄组别分類的呼吸道合胞病毒（RSV）诊断市场

  • 成人
  • 老年人
  • 儿童

第十五章 区域性呼吸道合胞病毒（RSV）诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 RSV诊断市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国呼吸道合胞病毒诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Roche Diagnostics International AG
    • QuidelOrtho Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Meridian Bioscience, Inc.
    • DiaSorin SpA
    • QIAGEN NV
Product Code: MRR-C002B1C99841

The RSV Diagnostics Market is projected to grow by USD 2.40 billion at a CAGR of 9.37% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.17 billion
Estimated Year [2025] USD 1.28 billion
Forecast Year [2032] USD 2.40 billion
CAGR (%) 9.37%

Comprehensive framing of RSV diagnostic priorities, technology convergence, clinical utility, and the operational levers that influence testing adoption across care settings

This executive summary distills current dynamics in diagnostics for respiratory syncytial virus, synthesizing clinical, technological, and commercial developments that matter for laboratory directors, clinical strategists, and product leaders. Diagnostics for RSV have moved from episodic pandemic-driven attention to an integrated element of respiratory disease management, informed by improved surveillance, expanded point-of-care capabilities, and evolving clinical guidelines. The introduction establishes the clinical imperative: timely, accurate testing informs therapeutic decisions, cohorting in institutions, and public health responses. It also frames the analytical approach used in the report, which emphasizes diagnostic pathways, technology adoption, product ecosystems, and end-user needs.

Building on that foundation, the introduction highlights the intersection of new molecular modalities, advanced immunoassays, and rapid formats that together broaden diagnostic accessibility. The report places equal emphasis on instruments, kits, and reagents as interdependent components of diagnostic deployment, and on the distribution and sample collection systems that enable real-world use. Finally, the introduction previews strategic themes explored in depth: how technology convergence, regulatory shifts, and reimbursement dynamics are reshaping testing practice across a wide set of clinical and non-clinical settings.

How technological convergence, decentralization of testing capabilities, and evolving clinical workflows are reshaping RSV diagnostics and care pathway decisions

The diagnostics landscape for RSV is undergoing transformative shifts driven by technological innovation, changing clinical practice, and system-level imperatives to improve rapid respiratory pathogen detection. Molecular platforms have migrated from centralized laboratories toward near-patient and decentralized settings, enabling earlier detection and more targeted clinical action. At the same time, immunoassays have improved analytic sensitivity through chemiluminescence and immunofluorescence approaches, narrowing the gap between rapidity and accuracy. Adoption of isothermal amplification and refined lateral flow chemistries illustrates a broader trend: technologies once siloed by setting are converging to meet diverse use-case requirements.

Concurrently, end-user expectations and care pathways are evolving. Hospitals and diagnostic laboratories increasingly integrate multiplexed testing strategies to differentiate RSV from other respiratory pathogens, while clinics and home care settings prioritize user-friendly rapid tests that support quick triage. Academic institutes continue to drive validation studies and novel assay development, whereas commercial entities accelerate scale-up of instruments, kits, and reagents to support distributed testing networks. These shifts are reinforced by an emphasis on standardized sample types such as nasopharyngeal swabs and saliva, which facilitate easier collection and broader testing accessibility. Together, these dynamics are reshaping how diagnostics are developed, validated, and delivered across the continuum of care.

Assessment of the cumulative operational effects of United States tariff adjustments in 2025 on supply chain resilience, procurement strategy, and diagnostic continuity

Tariff adjustments and trade policy changes implemented in the United States in 2025 created a ripple effect across diagnostic supply chains, influencing procurement strategies, sourcing decisions, and cost structures for instruments, kits, and reagents. Manufacturers and distributors experienced shifts in component sourcing, prompting a reevaluation of supplier portfolios and an acceleration of nearshoring initiatives for critical items such as analyzers, PCR machines, buffers, and enzymes. As a result, procurement teams began to place greater emphasis on supplier diversification and contractual flexibility to mitigate future trade-related disruptions.

In response, several diagnostic firms adjusted manufacturing footprints and logistics pathways to preserve service continuity for clinics, hospital laboratories, and diagnostic labs. These adjustments affected how products reached end users through both offline and online channels, with distributors optimizing inventory allocation across regions. The tariffs also encouraged stronger collaboration between instrument vendors and kit and reagent suppliers, given the interdependence of analyzers, PCR machines, saliva collection kits, swab collection kits, and reagent supplies. Overall, the 2025 tariff environment reinforced the importance of supply chain resilience and contractual agility in sustaining diagnostic availability and minimizing disruptions to clinical testing programs.

Integrated segmentation analysis linking test types, product ecosystems, technology platforms, end-user settings, sample types, distribution channels, and patient age cohorts to guide strategic focus

A rigorous segmentation lens clarifies where value and risk concentrate across the RSV diagnostics space. By test type, distinctions among immunoassay, molecular test, and rapid test categories reveal distinct performance and deployment profiles, with immunoassays further differentiated by chemiluminescence immunoassay, enzyme linked immunosorbent assay, and immunofluorescence assay modalities; molecular tests further divided into isothermal amplification, next generation sequencing, and real time polymerase chain reaction methods; and rapid tests differentiated across lateral flow assay and microfluidic assay formats. Each of these subcategories presents unique trade-offs in throughput, sensitivity, and point-of-care suitability, informing where laboratories and clinicians prioritize investment.

Examining products clarifies ecosystem dependencies among instruments, kits, and reagents, with analyzers and PCR machines serving as foundational hardware, saliva and swab collection kits defining preanalytical workflows, and buffers and enzymes enabling core assay chemistry. The technology platform perspective, which includes ELISA, immunofluorescence, and PCR, highlights the technical approaches that underpin assay performance and regulatory pathways. End-user segmentation spans academic institutes, clinics, diagnostic laboratories, home care, and hospital laboratories, reflecting varying operational demands and purchasing processes. Sample type distinctions among blood, nasopharyngeal swab, and saliva influence both clinical acceptance and logistics, while distribution channels across offline and online paths determine accessibility and time-to-result. Age group segmentation across adult, geriatric, and pediatric populations further refines clinical use cases and regulatory considerations. Taken together, these lenses enable decision-makers to align product development, distribution strategies, and validation efforts with real-world diagnostic needs.

Regional diagnostic priorities and operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and supply strategies

Regional dynamics shape diagnostic priorities, reimbursement realities, and operational constraints in ways that directly influence technology adoption and deployment strategies. In the Americas, clinical networks and hospital systems prioritize integrated laboratory workflows and rapid access to confirmatory molecular testing, while point-of-care adoption grows in outpatient clinics and community health settings. Manufacturers focus on scalable instrument platforms and compatible kits and reagents to support broad adoption across different clinical tiers.

In Europe, the Middle East & Africa, regulatory harmonization efforts and varying reimbursement environments create a heterogeneous landscape where decentralization gains traction in some markets while centralized laboratory testing remains dominant in others. Investment in sample collection systems and cold chain logistics is a recurring regional priority. In Asia-Pacific, high-volume diagnostic networks, rapid technology uptake, and strong manufacturing capabilities accelerate availability of diverse test formats, from high-throughput analyzers to rapid lateral flow assays and microfluidic solutions. Across regions, distribution channels and age group considerations influence how suppliers tailor product bundles and support services to meet local clinical and operational needs.

How diagnostic manufacturers and specialized suppliers are aligning platform strategies, partnerships, and supply chain capabilities to accelerate clinical adoption and support diverse end users

Leading diagnostic companies and specialized suppliers continue to drive innovation and operational scale in the RSV testing landscape, leveraging platform advantages and strategic partnerships to expand reach. Key players concentrate on strengthening their instrument ecosystems while ensuring compatibility with a broad range of kits and reagents, thereby lowering barriers for laboratory integration and enabling smoother procurement cycles. Strategic collaborations with academic institutes and clinical networks support validation efforts and expedite clinical adoption where regulatory pathways allow.

Commercial strategies increasingly emphasize after-sales support, assay validation services, and digital enablement to link test results to care pathways. Firms that invest in robust quality systems, regulatory expertise, and resilient supply chains position themselves to serve hospitals, diagnostic laboratories, clinics, and home care settings effectively. Moreover, companies that design flexible business models for distribution-balancing offline channel relationships with growing online procurement-can better navigate regional differences in purchasing behavior and logistics requirements. Ultimately, success hinges on aligning product portfolios with technical expectations across ELISA, immunofluorescence, and PCR platforms while addressing sample type preferences and user capabilities.

Practical strategic actions for diagnostic leaders to strengthen supply chain resilience, validate clinical performance, and align products with diverse care settings and user needs

Industry leaders should prioritize a set of pragmatic actions to translate diagnostic science into sustained clinical impact and commercial viability. First, strengthen supply chain resilience by diversifying component sourcing and negotiating flexible contracts that accommodate tariff-driven variability and logistics disruptions. Second, invest in validation partnerships with academic institutes and hospital laboratories to generate independent performance evidence across key sample types such as nasopharyngeal swab and saliva, and to demonstrate clinical utility across adult, geriatric, and pediatric cohorts. These partnerships will help accelerate clinical acceptance and inform reimbursement discussions.

Third, design product bundles that interoperate across instruments, kits, and reagents; compatibility reduces procurement friction for diagnostic laboratories and hospital networks. Fourth, tailor commercialization strategies to regional nuances, leveraging hybrid distribution approaches that combine offline channel strength with online procurement efficiency. Fifth, advance user-centered rapid test formats for clinics and home care, while supporting centralized laboratories with high-throughput molecular solutions. Finally, embed digital result reporting and data analytics into test offerings to support clinicians, public health surveillance, and post-market performance monitoring. Together, these actions will strengthen clinical relevance and long-term resilience.

Transparent multi-source methodology combining literature synthesis, regulatory review, technical validation, and stakeholder interviews to deliver rigorous diagnostic insights and segmentation clarity

This research synthesizes peer-reviewed literature, regulatory filings, clinical guidance documents, product technical specifications, and primary stakeholder interviews to construct a multi-dimensional view of RSV diagnostics. The methodology combined systematic review of recent scientific publications and technical white papers with structured interviews of laboratory directors, clinical end users, and industry subject matter experts. The analysis prioritized cross-validation of technical claims against independently reported performance data and real-world implementation feedback.

Segmentation frameworks were developed to capture the interplay among test type, product, technology platform, end user, sample type, distribution channel, and age group, enabling granular insight into where diagnostic performance and adoption risk converge. Regional analyses integrated policy and procurement context to account for operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific. The approach emphasizes transparent assumptions, documented sources for technical parameters, and an evidence-led narrative designed to support strategic decision-making by diagnostics manufacturers, laboratory leaders, and clinical stakeholders.

Synthesis of diagnostic technology strengths, operational imperatives, and strategic priorities that together determine lasting clinical and commercial success in RSV testing

In conclusion, the landscape of RSV diagnostics is defined by a dynamic balance between technological capability and real-world usability. Molecular, immunoassay, and rapid formats each contribute distinct strengths to clinical pathways, and their convergence creates opportunities to improve patient outcomes through more timely and accurate detection. Supply chain and trade developments have underscored the need for resilient sourcing and flexible operational planning, while regional and end-user heterogeneity demands tailored approaches to product design and commercialization.

Decision-makers should therefore pursue integrated strategies that link robust technical validation with pragmatic deployment planning, including partnerships with clinical and academic stakeholders. By aligning instrument ecosystems, kits, and reagents with user requirements across hospital laboratories, diagnostic labs, clinics, and home care settings, organizations can enhance diagnostic impact. Ultimately, the most effective strategies will be those that combine technical excellence with adaptability to regulatory, procurement, and operational realities across regions and patient cohorts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of point-of-care molecular testing for RSV enabling decentralized patient management and faster treatment decisions
  • 5.2. Integration of multiplex respiratory panels combining RSV, influenza, and SARS-CoV-2 detection for comprehensive seasonal virus surveillance
  • 5.3. Adoption of isothermal amplification technologies in RSV diagnostics driving improved sensitivity and reduced turnaround time in outpatient settings
  • 5.4. Increasing demand for home-based RSV testing kits supported by telehealth platforms and remote patient monitoring solutions
  • 5.5. Growing focus on pediatric and neonatal RSV screening protocols in hospitals to reduce severe infection rates and optimize resource allocation
  • 5.6. Emergence of digital health and AI-driven interpretation tools enhancing the accuracy and workflow efficiency of RSV diagnostic laboratories
  • 5.7. Regulatory approvals for next generation sequencing assays targeting RSV genetic subtyping and antiviral resistance profiling in clinical trials
  • 5.8. Impact of shifting RSV seasonality patterns post-COVID-19 pandemic on testing volumes and public health surveillance strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RSV Diagnostics Market, by Test Type

  • 8.1. Immunoassay
    • 8.1.1. Chemiluminescence Immunoassay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
    • 8.1.3. Immunofluorescence Assay
  • 8.2. Molecular Test
    • 8.2.1. Isothermal Amplification
    • 8.2.2. Next Generation Sequencing
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Rapid Test
    • 8.3.1. Lateral Flow Assay
    • 8.3.2. Microfluidic Assay

9. RSV Diagnostics Market, by Product

  • 9.1. Instruments
    • 9.1.1. Analyzers
    • 9.1.2. PCR Machines
  • 9.2. Kits
    • 9.2.1. Saliva Collection Kits
    • 9.2.2. Swab Collection Kits
  • 9.3. Reagents
    • 9.3.1. Buffers
    • 9.3.2. Enzymes

10. RSV Diagnostics Market, by Technology Platform

  • 10.1. ELISA
  • 10.2. Immunofluorescence
  • 10.3. PCR

11. RSV Diagnostics Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Home Care
  • 11.5. Hospital Laboratories

12. RSV Diagnostics Market, by Sample Type

  • 12.1. Blood
  • 12.2. Nasopharyngeal Swab
  • 12.3. Saliva

13. RSV Diagnostics Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. RSV Diagnostics Market, by Age Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. RSV Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. RSV Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. RSV Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. Roche Diagnostics International AG
    • 18.3.3. QuidelOrtho Corporation
    • 18.3.4. Thermo Fisher Scientific Inc.
    • 18.3.5. bioMerieux SA
    • 18.3.6. Becton, Dickinson and Company
    • 18.3.7. Danaher Corporation
    • 18.3.8. Meridian Bioscience, Inc.
    • 18.3.9. DiaSorin S.p.A.
    • 18.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. RSV DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. RSV DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RSV DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET